12399456https://www.upal.com.my/zh/feeds/jobFeedKwongwahArray ( [0] => HTTP/1.1 200 OK [1] => Date: Sat, 11 Apr 2026 17:46:41 GMT [2] => Content-Type: text/xml; charset=utf-8 [3] => Connection: close [4] => Cache-Control: no-cache, private [5] => Cache-Control: no-cache, no-store, must-revalidate [6] => Set-Cookie: UpalLiveSession=eyJpdiI6ImJkZk9uZnVBYkw2MklhQjI3ZERRWEE9PSIsInZhbHVlIjoiQnY4SDBEMzBDVHRTVzFwTmlzRFZFN3Voc3ZBOHA0SjE5NVN6cGJRM0xlR1VwTVR2RGUyT1pSYnBGVXFNRjdmS29JWTRsc1R4YzkrMWkzeU9ITjg1NGc9PSIsIm1hYyI6IjFiMjk2NzcxNDY0NTVjYWU3OWExYjRhOTQwZjI4ZGVhZDE5OTVlNmY5MGMyZTNjYTEzYTRmZDQ4MzA2NmQ0MjAifQ%3D%3D; expires=Tue, 10-Apr-2029 17:46:41 GMT; Max-Age=94608000; path=/; HttpOnly [7] => x-frame-options: SAMEORIGIN [8] => x-content-type-options: nosniff [9] => x-xss-protection: 1; mode=block [10] => referrer-policy: strict-origin-when-cross-origin [11] => permissions-policy: geolocation=(), microphone=(), camera=() [12] => content-security-policy: default-src * 'unsafe-inline' 'unsafe-eval' data: blob:; script-src * 'unsafe-inline' 'unsafe-eval' data: blob:; style-src * 'unsafe-inline' data:; img-src * data: blob:; font-src * data:; connect-src *; frame-src *; object-src *; media-src *; child-src *; [13] => Server: cloudflare [14] => x-robots-tag: noindex, nofollow, nosnippet, noarchive [15] => strict-transport-security: max-age=31536000; includeSubDomains; preload [16] => expires: Sun, 12 Apr 2026 17:46:41 GMT [17] => vary: Accept-Encoding [18] => Report-To: {"group":"cf-nel","max_age":604800,"endpoints":[{"url":"https://a.nel.cloudflare.com/report/v4?s=i8MrrW2%2F%2FJkqNZNlrta8ruLgOL83ifoA5kK51gXg7JAPP6IkvegtG%2BtdoPOkG8xo60ID7OCgRbH95hILC1f9pgrJYJJaIW%2Fw1GqMP1JPitxqpusdSxQa8A5pvSOmWFh7Fxo%3D"}]} [19] => cf-cache-status: DYNAMIC [20] => Nel: {"report_to":"cf-nel","success_fraction":0.0,"max_age":604800} [21] => Speculation-Rules: "/cdn-cgi/speculation" [22] => Server-Timing: cfCacheStatus;desc="DYNAMIC" [23] => Server-Timing: cfEdge;dur=9,cfOrigin;dur=711 [24] => CF-RAY: 9eabcfe77cbe5027-LAX [25] => alt-svc: h3=":443"; ma=86400 ) 789

卫生总监拿督诺希山表示，虽然新加坡宣布召回三种常见高血压氯沙坦（Losartan）药，但我国药物管理局（PBKD）早在本月7日，就已取消7种含有氯沙坦成分的药物注册，并下令回收相关药物。

他今日发文告指出，卫生部已向相关的公司下达指令，要他们即刻从市场上召回这7种药物，因为这些常见的高血压药物内含有氯沙坦（Losartan）成分，长期服用可能致癌。

“因此，卫生部相信，此刻我国市场上已无法寻获这7种药物。”

根据卫生部文告指出，被撤销注册的药物，全都生产自印度，分别为Hetero Labs Limited生产的LOSAGEN 50及LOSAGEN 100；Intas Pharm Ltd生产的Losartas 50mg Tablets及Losartas 100mg Tablets；以及Torrent Pharmaceuticals Ltd生产的TOZAAR PLUS LS 50/12.5mg Tablet、Tozaar 50mg Tablet及Tozaar Tablets 100mg。

卫生部也促请民众必须食用经药物管理局注册及批准的任何药品及保健品。民众可到国家药剂监管机构（NPRA）的网站（www.npra.gov.my）或透过谷歌Play商店下载手机APP（NPRA Product Status），查验相关药物是否已经取得注册。

根据新加坡《早报》报道指，该国卫生科学局指，化验显示，由印度制药商Hetero Labs Limited制造的氯沙坦药物被化验出含有超出国际标准的NMBA杂质，这种杂质据称可能致癌。

报道也指，服用这些药并没有立即的健康风险，因此病患无须自行停药。患者可跟医疗人员讨论更换药物和新治疗方案。

---

// // // //